Home
INSM
INSM News

Latest Insmed Incorporated (INSM) News on November 27, 2025

Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook?

Simply Wall St.

a day ago

Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook?

What Catalysts Are Shaping the New Narrative for Insmed?

Simply Wall St.

2 days ago

What Catalysts Are Shaping the New Narrative for Insmed?

Insmed (INSM) Rose Following Drug Approval

Insider Monkey

2 days ago

Insmed (INSM) Rose Following Drug Approval

This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.

24/7 Wall St.

3 days ago

This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

Zacks

8 days ago

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

Argus Research

8 days ago

Daily – Vickers Top Buyers & Sellers for 11/19/2025

MT Newswires

9 days ago

Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

PR Newswire

9 days ago

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Here’s What Lifted Insmed Incorporated (INSM) in Q3

Insider Monkey

10 days ago

Here’s What Lifted Insmed Incorporated (INSM) in Q3

A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge

Simply Wall St.

12 days ago

A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

PR Newswire

14 days ago

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Business Wire

21 days ago

MSCI Equity Indexes November 2025 Index Review

MT Newswires

21 days ago

Insmed Insider Sold Shares Worth $4,985,911, According to a Recent SEC Filing

Insmed To Present at November and December 2025 Investor Conferences

PR Newswire

22 days ago

Insmed To Present at November and December 2025 Investor Conferences

Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3

Insider Monkey

24 days ago

Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3

MT Newswires

a month ago

RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating

MT Newswires

a month ago

UBS Adjusts Insmed Price Target to $223 From $194, Maintains Buy Rating

MT Newswires

a month ago

Truist Raises Price Target on Insmed to $214 From $139, Keeps Buy Rating

A Look at Insmed (INSM) Valuation Following EU Brensocatib Milestone and ARIKAYCE Revenue Upgrade

Simply Wall St.

a month ago

A Look at Insmed (INSM) Valuation Following EU Brensocatib Milestone and ARIKAYCE Revenue Upgrade

Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ...

GuruFocus.com

a month ago

Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ...

Insmed Screams To A 25-Year High, While IBD 50's Argenx Slides

Investor's Business Daily

a month ago

Insmed Screams To A 25-Year High, While IBD 50's Argenx Slides

Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates

Zacks

a month ago

Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates

MT Newswires

a month ago

Insmed Q3 Loss Widens, Revenue Rises; Shares up

MT Newswires

a month ago

UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating

Why Biotech’s Rally Can Last This Time

The Wall Street Journal

a month ago

Why Biotech’s Rally Can Last This Time

Insmed Insiders Sold US$36m Of Shares Suggesting Hesitancy

Simply Wall St.

2 months ago

Insmed Insiders Sold US$36m Of Shares Suggesting Hesitancy

How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections

Simply Wall St.

2 months ago

How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections

Ohio Retirement Fund Invests in Insmed Incorporated (INSM)

Insider Monkey

2 months ago

Ohio Retirement Fund Invests in Insmed Incorporated (INSM)

Is IPF the Next Big Market Opportunity for United Therapeutics?

Zacks

2 months ago

Is IPF the Next Big Market Opportunity for United Therapeutics?

Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

Insider Monkey

2 months ago

Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

PR Newswire

2 months ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 09/16/2025

MT Newswires

2 months ago

Insmed Insider Sold Shares Worth $1,453,900, According to a Recent SEC Filing

MT Newswires

2 months ago

Insmed Insider Sold Shares Worth $11,129,927, According to a Recent SEC Filing

Insmed (INSM) Reported Impressive Results from the Phase 2 Trial of Its Inhalation Powder

Insider Monkey

2 months ago

Insmed (INSM) Reported Impressive Results from the Phase 2 Trial of Its Inhalation Powder

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

3 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Insmed Insider Sold Shares Worth $26,941,272, According to a Recent SEC Filing

Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri

Pharmaceutical Technology

3 months ago

Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

Zacks

3 months ago

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It

Investor's Business Daily

3 months ago

Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It

Investor's Business Daily

3 months ago

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It

Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

PR Newswire

3 months ago

Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

GlobeNewswire

3 months ago

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 08/22/2025

How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story

Simply Wall St.

3 months ago

How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story

Magazine: Big biopharma take on the ADC challenge

Pharmaceutical Technology

3 months ago

Magazine: Big biopharma take on the ADC challenge

MT Newswires

3 months ago

Insmed Insider Sold Shares Worth $1,295,000, According to a Recent SEC Filing

Insmed To Present at September Investor Conferences

PR Newswire

3 months ago

Insmed To Present at September Investor Conferences

MT Newswires

3 months ago

Morgan Stanley Raises Price Target on Insmed to $144 From $126, Keeps Equalweight Rating

MT Newswires

3 months ago

Insmed Insider Sold Shares Worth $881,470, According to a Recent SEC Filing

MT Newswires

3 months ago

William Blair Initiates Insmed at Outperform

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Barchart

3 months ago

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

Simply Wall St.

3 months ago

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $5,879,089, According to a Recent SEC Filing

Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

Insider Monkey

5 months ago

Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107

Insider Monkey

5 months ago

Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107

Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Insider Monkey

5 months ago

Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

Insider Monkey

5 months ago

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

BioPharma Dive

5 months ago

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

Insmed (INSM) Soars After Raising $650 million

Insider Monkey

5 months ago

Insmed (INSM) Soars After Raising $650 million

Insmed Inc (INSM) Soars 30% on Impressive Study

Insider Monkey

5 months ago

Insmed Inc (INSM) Soars 30% on Impressive Study

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing

MT Newswires

5 months ago

Insmed Prices $750 Million Common Stock Offering

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

PR Newswire

5 months ago

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Insider Monkey

5 months ago

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

MT Newswires

5 months ago

Insmed Plans $650 Million Public Offering

Insmed Announces Proposed $650 Million Public Offering of Common Stock

PR Newswire

5 months ago

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Benzinga

6 months ago

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

MT Newswires

6 months ago

Update: BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating

Insmed Stock Jumps 29% on Encouraging PAH Study Results

Zacks

6 months ago

Insmed Stock Jumps 29% on Encouraging PAH Study Results

Insmed Stock Skyrockets Following Experimental Drug Trial Results

Barrons.com

6 months ago

Insmed Stock Skyrockets Following Experimental Drug Trial Results

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

Investor's Business Daily

6 months ago

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Top Premarket Gainers

MT Newswires

6 months ago

Insmed Says Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

PR Newswire

6 months ago

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $878,292, According to a Recent SEC Filing

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $451,535, According to a Recent SEC Filing

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

6 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $1,833,779, According to a Recent SEC Filing

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

PR Newswire

6 months ago

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $1,886,957, According to a Recent SEC Filing

MT Newswires

6 months ago

Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

PR Newswire

6 months ago

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $633,654, According to a Recent SEC Filing

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $708,681, According to a Recent SEC Filing

Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

6 months ago

Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects

Zacks

6 months ago

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects

MT Newswires

6 months ago

Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target

Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results

Simply Wall St.

7 months ago

Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

Zacks

7 months ago

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

MT Newswires

7 months ago

UBS Adjusts Price Target on Insmed to $109 From $110, Maintains Buy Rating

Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain?

Insider Monkey

7 months ago

Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain?

MT Newswires

7 months ago

RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Zacks

7 months ago

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

MT Newswires

7 months ago

Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained

Associated Press Finance

7 months ago

Insmed: Q1 Earnings Snapshot

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

PR Newswire

7 months ago

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Insider Monkey

7 months ago

Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

MT Newswires

7 months ago

Insmed Insider Sold Shares Worth $495,668, According to a Recent SEC Filing

Share on Social Networks: